Cooke RW, Drury JA, Mountford R, Clark D Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1712-5. doi: 10.1167/iovs.03-1303.
Early Treatment For Retinopathy Of Prematurity Cooperative Group Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003 Dec;121(12):1684-94. doi: 10.1001/archopht.121.12.1684.
Flynn JT, Chan-Ling T Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol. 2006 Jul;142(1):46-59. doi: 10.1016/j.ajo.2006.02.018.
Gaynon MW Rethinking STOP-ROP: is it worthwhile trying to modulate excessive VEGF levels in prethreshold ROP eyes by systemic intervention? A review of the role of oxygen, light adaptation state, and anemia in prethreshold ROP. Retina. 2006 Sep;26(7 Suppl):S18-23. doi: 10.1097/01.iae.0000244292.86627.1e.
Itakura H, Kishi S, Kotajima N, Murakami M Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Ophthalmology. 2004 Oct;111(10):1880-4. doi: 10.1016/j.ophtha.2004.03.035.
Kieselbach GF, Ramharter A, Baldissera I, Kralinger MT Laser photocoagulation for retinopathy of prematurity: structural and functional outcome. Acta Ophthalmol Scand. 2006 Feb;84(1):21-6. doi: 10.1111/j.1600-0420.2005.00548.x.
Kychenthal A, Dorta P, Katz X Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina. 2006 Sep;26(7 Suppl):S11-5. doi: 10.1097/01.iae.0000244285.79004.e6.
Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol. 2000 Apr;156(4):1337-44. doi: 10.1016/S0002-9440(10)65004-3.
Lermann VL, Fortes Filho JB, Procianoy RS The prevalence of retinopathy of prematurity in very low birth weight newborn infants. J Pediatr (Rio J). 2006 Jan-Feb;82(1):27-32. doi: 10.2223/JPED.1433.
Phelps DL; ETROP Cooperative Group The Early Treatment for Retinopathy of Prematurity study: better outcomes, changing strategy. Pediatrics. 2004 Aug;114(2):490-1. doi: 10.1542/peds.114.2.490. No abstract available.
Pierce EA, Foley ED, Smith LE Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996 Oct;114(10):1219-28. doi: 10.1001/archopht.1996.01100140419009. Erratum In: Arch Ophthalmol 1997 Mar;115(3):427.
Quinn GE, Schaffer DB, Johnson L A revised classification of retinopathy of prematurity. Am J Ophthalmol. 1982 Dec;94(6):744-9. doi: 10.1016/0002-9394(82)90298-7.
Yoo MH, Hyun HJ, Koh JY, Yoon YH Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7. doi: 10.1167/iovs.05-0376.
Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
